Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 2/20 | 0.51 |
| ▸ | CNR2 | P34972 | 4/20 | 0.50 |
| ▸ | CNR1 | P21554 | 1/20 | 0.50 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.47 |
| ▸ | ICMT | O60725 | 2/20 | 0.46 |
| ▸ | HTR3A | P46098 | 5/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.43 |
| ▸ | MPO | P05164 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4494230 | 0.86 | CNR2 (0.61) | CNR2CNR1KDM4CICMTHTR3A | |
| SCHEMBL2816604 | 0.84 | CNR2 (0.51) | CNR2CNR1KDM4CICMTHTR3A | |
| SCHEMBL25403772 | 0.82 | CNR1 (0.50) | CNR2CNR1KDM4CICMTHTR3A | |
| SCHEMBL31083818 | 0.82 | CNR1 (0.50) | CNR2CNR1KDM4CICMTHTR3A | |
| SCHEMBL12485447 | 0.80 | KDM4E (0.54) | CNR2CNR1KDM4CHTR3A | |
| SCHEMBL2817707 | 0.80 | ALDH1A1 (0.50) | CNR2CNR1KDM4CHTR3A | |
| SCHEMBL27335551 | 0.78 | CNR2 (0.55) | CNR2CNR1KDM4CICMT | |
| SCHEMBL15557151 | 0.76 | HTR3A (0.58) | CNR2CNR1KDM4CHTR3A | |
| SCHEMBL6590622 | 0.75 | CNR2 (0.48) | CNR2CNR1ICMTHTR3A | |
| SCHEMBL2433258 | 0.75 | KDM4E (0.55) | KDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100249123-A1 | NOVEL BENZAMIDE DERIVATIVES AS MODULATORS OF THE FOLLICLE STIMULATING HORMONE | ADDEX PHARMA SA (CH) | 2010-09-30 | — | — | US | claimed |
| US-20100249123-A1 | NOVEL BENZAMIDE DERIVATIVES AS MODULATORS OF THE FOLLICLE STIMULATING HORMONE | ADDEX PHARMA SA (CH) | 2010-09-30 | — | — | US | disclosed |
| EP-2134676-A2 | NOVEL BENZAMIDE DERIVATIVES AS MODULATORS OF THE FOLLICLE STIMULATING HORMONE | Addex Pharma SA (CH) | 2009-12-23 | — | — | EP | disclosed |
| WO-2008117175-A2 | NOVEL BENZAMIDE DERIVATIVES AS MODULATORS OF THE FOLLICLE STIMULATING HORMONE | ADDEX PHARMA SA (CH) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249123-A1 | NOVEL BENZAMIDE DERIVATIVES AS MODULATORS OF THE FOLLICLE STIMULATING HORMONE | FSHR, GNRHR, SHBG | HTR6 797/4885CNR2 198/4885CNR1 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.